| For: | Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017; 8(1): 1-20 [PMID: 28246582 DOI: 10.5306/wjco.v8.i1.1] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v8/i1/1.htm |
| Number | Citing Articles |
| 1 |
Huan-Wei Liang, Yang Liu, Xin-Bin Pan. Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer. Aging 2024; doi: 10.18632/aging.205425
|
| 2 |
Liuxin Wang, Weixiang Kong, Bing Liu, Xueqing Zhang. Proliferating cell nuclear antigen promotes cell proliferation and tumorigenesis by up-regulating STAT3 in non-small cell lung cancer. Biomedicine & Pharmacotherapy 2018; 104 doi: 10.1016/j.biopha.2018.05.071
|
| 3 |
Marina C Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Özgüroğlu, Davey Daniel, David Vicente, Shuji Murakami, Corey Langer, Suresh Senan, David Spigel, Anna Rydén, Yiduo Zhang, Cathy O'Brien, Phillip A Dennis, Scott J Antonia. Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer. Future Oncology 2021; 17(10) doi: 10.2217/fon-2020-1102
|
| 4 |
Kimia ÇEPNİ, Tuğçe DURSUN UÇAR, Tuğçe Hilal UÇGUN, Huriye Senay KIZILTAN. Prognostic Significance of Lymphocyte Percentage and IL-6 Level in Patients Undergoing Radiotherapy for Advanced Lung Cancer. Bezmialem Science 2026; 14(1) doi: 10.14235/bas.galenos.2025.98624
|
| 5 |
Gautam Kumar, Shweta Khandibharad, Shailza Singh. Targeting IL-6/STAT3 signaling to mitigate sarcopenia: Insights from immuno-metabolic crosstalk in NSCLC. Biochemical and Biophysical Research Communications 2025; 786 doi: 10.1016/j.bbrc.2025.152727
|
| 6 |
Yu Katagiri, Keiichi Jingu, Takaya Yamamoto, Haruo Matsushita, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Kazuya Takeda, Shun Tasaka, Noriyuki Kadoya. Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer. Japanese Journal of Radiology 2021; 39(6) doi: 10.1007/s11604-021-01091-y
|
| 7 |
Soyeong Jun, Nikhil A. Shukla, Greg Durm, Angela B. Hui, Sha Cao, Apar Kishor Ganti, Salma K. Jabbour, Christian Kunder, Ash A. Alizadeh, Nasser H. Hanna, Maximilian Diehn. Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC. Journal of Thoracic Oncology 2024; 19(10) doi: 10.1016/j.jtho.2024.06.024
|
| 8 |
|
| 9 |
Yan Li, Kum-Hee Yun, Hyeri Lee, Sung-Ho Goh, Yang-Gun Suh, Yongdoo Choi. Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo. Biomaterials 2019; 197 doi: 10.1016/j.biomaterials.2019.01.004
|
| 10 |
Xiaobo Cheng, Jing Wang, Chenli Qiu, Yanling Jin, Bili Xia, Ran Qin, Huiliang Hu, Jia Yan, Xiaoyan Zhang, Jianqing Xu. Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial. Clinical Immunology 2022; 238 doi: 10.1016/j.clim.2022.108992
|
| 11 |
Ashwini Arunachalam, Sneha Sura, John Murphy, Paul Conkling, Jerome Goldschmidt, Jian Wu. Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer. PLOS ONE 2024; 19(11) doi: 10.1371/journal.pone.0314156
|
| 12 |
Jerold Loh, Jia Li Low, Manavi Sachdeva, Peter QJ Low, Rachel Su Jen Wong, Yiqing Huang, Puey Ling Chia, Ross A Soo. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer. Expert Review of Anticancer Therapy 2023; 23(9) doi: 10.1080/14737140.2023.2245140
|
| 13 |
Abdul Rahman Jazieh, Huseyin Cem Onal, Daniel Shao Weng Tan, Ross A. Soo, Kumar Prabhash, Amit Kumar, Reto Huggenberger, Stephen Robb, Byoung-Chul Cho. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study. Journal of Thoracic Oncology 2021; 16(10) doi: 10.1016/j.jtho.2021.05.003
|
| 14 |
Shadi Hamouri, Nasr Alrabadi, Sebawe Syaj, Hassan Abushukair, Obada Ababneh, Leen Al-Kraimeen, Majd Al-Sous, Erich Hecker. Atrial resection for T4 non-small cell lung cancer with left atrium involvement: a systematic review and meta-analysis of survival. Surgery Today 2023; 53(3) doi: 10.1007/s00595-021-02446-8
|
| 15 |
Ranpu Wu, Shaorong Yu, Jinjun Ye, Yimin Wang, Zhiting Zhao, Hongbing Liu, Yong Song. A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.692703
|
| 16 |
Agnieszka Wojskowicz, Piotr Skalij, Dominika Hempel, Łukasz Zalewski, Monika Konopka-Filippow, Iwona Sidorkiewicz, Agnieszka Krzystyniak, Ewa Sierko. A Real-World, Single-Center, Observational Retrospective Experience of Durvalumab Treatment After Concomitant Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Cancers 2026; 18(6) doi: 10.3390/cancers18061044
|
| 17 |
Xander Verbeke, Gilles Defraene, Walter De Wever, Maarten Lambrecht, Els Wauters. Pneumonitis after chemoradiotherapy and/or immunotherapy for stage III and IV non-small cell lung cancer is characterized by specific radiologic and quantitative CT features. Clinical and Translational Radiation Oncology 2026; 60 doi: 10.1016/j.ctro.2026.101215
|
| 18 |
Mario Ouwens, Annie Darilay, Yiduo Zhang, Pralay Mukhopadhyay, Helen Mann, James Ryan, Phillip A. Dennis. Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study. Current Therapeutic Research 2021; 95 doi: 10.1016/j.curtheres.2021.100640
|
| 19 |
Patrizia Ciammella, Salvatore Cozzi, Paolo Borghetti, Marco Galaverni, Valerio Nardone, Maria Paola Ruggieri, Matteo Sepulcri, Vieri Scotti, Alessio Bruni, Francesca Zanelli, Roberto Piro, Elena Tagliavini, Andrea Botti, Federico Iori, Emanuele Alì, Chiara Bennati, Marcello Tiseo. Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1325249
|
| 20 |
Tadashi Sakaguchi, Kentaro Ito, Naoki Furuya, Kei Morikawa, Kentaro Fujiwara, Yoichi Nishii, Takeo Inoue, Osamu Hataji, Masamichi Mineshita. Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy. Thoracic Cancer 2021; 12(13) doi: 10.1111/1759-7714.14005
|
| 21 |
Nobuyuki Yamamoto, Hideyuki Harada, Isamu Okamoto, Noriyuki Masuda, Kazushige Hayakawa, Miyako Satouchi, Toshinori Soejima, Makoto Nishio, Takuyo Kozuka, Koji Takeda, Masahiro Tanaka, Takashi Seto, Tomonari Sasaki, Hiroshi Tsubouchi, Yasuyuki Kakurai, Yasumasa Nishimura, Kazuhiko Nakagawa. Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2021; 22(2) doi: 10.1016/j.cllc.2020.12.012
|
| 22 |
Suna Zhou, Yinnan Meng, Xuefeng Sun, Zhicheng Jin, Wei Feng, Haihua Yang. The Critical Components for Effective Adaptive Radiotherapy in Patients with Unresectable Non-Small-Cell Lung Cancer: Who, When and How. Future Oncology 2022; 18(31) doi: 10.2217/fon-2022-0291
|
| 23 |
Chuan-Hsin Chang, Yue-Cune Chang. Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches. International Journal of Environmental Research and Public Health 2022; 19(21) doi: 10.3390/ijerph192114324
|
| 24 |
Jarushka Naidoo, Johan F. Vansteenkiste, Corinne Faivre-Finn, Mustafa Özgüroğlu, Shuji Murakami, Rina Hui, Xavier Quantin, Helen Broadhurst, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer 2022; 166 doi: 10.1016/j.lungcan.2022.02.003
|
| 25 |
Chuan-Hsin Chang, Chih-Cheng Chien, Yue-Cune Chang. The updated network meta-analysis of the therapeutic efficacies of lung cancer: A systematic review and meta-analysis. Tzu Chi Medical Journal 2025; 37(3) doi: 10.4103/tcmj.tcmj_264_24
|
| 26 |
Jun-Chieh J. Tsay, Benjamin G. Wu, Imran Sulaiman, Katherine Gershner, Rosemary Schluger, Yonghua Li, Ting-An Yie, Peter Meyn, Evan Olsen, Luisannay Perez, Brendan Franca, Joseph Carpenito, Tadasu Iizumi, Mariam El-Ashmawy, Michelle Badri, James T. Morton, Nan Shen, Linchen He, Gaetane Michaud, Samaan Rafeq, Jamie L. Bessich, Robert L. Smith, Harald Sauthoff, Kevin Felner, Ray Pillai, Anastasia-Maria Zavitsanou, Sergei B. Koralov, Valeria Mezzano, Cynthia A. Loomis, Andre L. Moreira, William Moore, Aristotelis Tsirigos, Adriana Heguy, William N. Rom, Daniel H. Sterman, Harvey I. Pass, Jose C. Clemente, Huilin Li, Richard Bonneau, Kwok-Kin Wong, Thales Papagiannakopoulos, Leopoldo N. Segal. Lower Airway Dysbiosis Affects Lung Cancer Progression. Cancer Discovery 2021; 11(2) doi: 10.1158/2159-8290.CD-20-0263
|
| 27 |
Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar, Richard Tuli. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. Journal for ImmunoTherapy of Cancer 2018; 6(1) doi: 10.1186/s40425-018-0361-7
|
| 28 |
Changjun He, Xue Bai, Yingbin Li, Haobo Sun, Xianglong Kong, Bicheng Fu, Lantao Chen, Kaibin Zhu, Pengju Li, Shidong Xu. Runt-related transcription factor 1 contributes to lung cancer development by binding to tartrate-resistant acid phosphatase 5. Cell Cycle 2019; 18(23) doi: 10.1080/15384101.2019.1678966
|
| 29 |
Yan Cui, Xuena Li, Bulin Du, Yao Diao, Yaming Li. <p>PD-L1 in Lung Adenocarcinoma: Insights into the Role of <sup>18</sup>F-FDG PET/CT</p>. Cancer Management and Research 2020; doi: 10.2147/CMAR.S256871
|
| 30 |
Yuting Kuang, Christine M. Pierce, Hsiu-Ching Chang, Alexandra Z. Sosinsky, Anne C. Deitz, Steven M. Keller, Ayman Samkari, Jennifer Uyei. Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis. Lung Cancer 2022; 174 doi: 10.1016/j.lungcan.2022.06.005
|
| 31 |
Jarushka Naidoo, Mizuki Nishino, Sandip Pravin Patel, Bairavi Shankar, Natasha Rekhtman, Peter Illei, Phillipe Camus. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2020; 21(5) doi: 10.1016/j.cllc.2020.02.025
|
| 32 |
Khalid Jazieh, Mohammadhadi Khorrami, Anas Saad, Mohamed Gad, Amit Gupta, Pradnya Patil, Vidya Sankar Viswanathan, Prabhakar Rajiah, Charles J Nock, Michael Gilkey, Pingfu Fu, Nathan A Pennell, Anant Madabhushi. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. Journal for ImmunoTherapy of Cancer 2022; 10(3) doi: 10.1136/jitc-2021-003778
|
| 33 |
Kerstin Gunnarsson, Louise Mövik, Niclas Pettersson, Anna Bäck, Jan Nyman, Andreas Hallqvist. Assessment of radiation pneumonitis and predictive factors in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. Acta Oncologica 2024; 63 doi: 10.2340/1651-226X.2024.40576
|
| 34 |
Juliana Machado-Rugolo, Alexandre Todorovic Fabro, Daniel Ascheri, Cecília Farhat, Alexandre Muxfeldt Ab'Saber, Vanessa Karen de Sá, Maria Aparecida Nagai, Teresa Takagaki, Ricardo Terra, Edwin Roger Parra, Vera Luiza Capelozzi. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non–small cell lung cancer. Human Pathology 2019; 83 doi: 10.1016/j.humpath.2018.08.026
|
| 35 |
Chih-Yen Chang, Yen-Chiao (Angel) Lu, Wen-Chien Ting, Tsu-Wang (David) Shen, Wen-Chen Peng. An artificial immune system with bootstrap sampling for the diagnosis of recurrent endometrial cancers. Open Medicine 2021; 16(1) doi: 10.1515/med-2021-0226
|
| 36 |
Dexiong Jiang, Yao Rao, Chunxi Zhang, Dan Wang, Xu Jiang, Huachuan Wang. Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study. Oncology Letters 2024; 28(2) doi: 10.3892/ol.2024.14508
|
| 37 |
Ajab Shereen, Kastelik Jack A, Loubani Mahmoud. Current medical and surgical management of lung cancer. Journal of Surgery and Surgical Research 2021; doi: 10.17352/2455-2968.000137
|
| 38 |
Federica Sotgia, Michael P. Lisanti. Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics. Oncotarget 2017; 8(40) doi: 10.18632/oncotarget.19677
|
| 39 |
L. Nicosia, L. Agolli, C. Reverberi, V. De Sanctis, L. Marinelli, G. Minniti, J. Di Muzio, M. Valeriani, M. F. Osti. Salvage radiotherapy with simultaneous integrated boost in non small-cell lung cancer patients with mediastinal relapse after surgery: a pilot study. Radiation Oncology 2018; 13(1) doi: 10.1186/s13014-018-1155-2
|
| 40 |
Yang Liu, Huan-Wei Liang, Xin-Bin Pan. Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients. Aging 2023; doi: 10.18632/aging.204781
|
| 41 |
Maria Mitsogianni, Nikolaos Mitsimponas, Felipe Crespo, Karl Axel Hartmann, Bernd Klosterhalfen, Sabine Haase, Aristoteles Giagounidis. Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report. Case Reports in Oncology 2018; 11(1) doi: 10.1159/000486640
|
| 42 |
Yanan Zhang, Zhehui Liu, Hongmin Wang, Fengfan Liang, Liqiong Zhu, Haifeng Liu. Association of metastatic nodal size with survival in non-surgical non-small cell lung cancer patients: Recommendations for clinical N staging. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.990540
|
| 43 |
Kevin Lu, Brian D. Woodward, Joshua Boys, Mark Onaitis, Hatim Husain. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC. Clinical Lung Cancer 2024; 25(1) doi: 10.1016/j.cllc.2023.08.012
|
| 44 |
Giulia Veronesi, Pierluigi Novellis, Emanuele Voulaz, Pietro Bruschini. Robotic assisted lung resection for locally advanced lung cancer. Expert Review of Respiratory Medicine 2020; 14(2) doi: 10.1080/17476348.2020.1697235
|
| 45 |
Nobuaki Mamesaya, Koji Muramatsu, Michitoshi Yabe, Hiroaki Kodama, Naoya Nishioka, Taichi Miyawaki, Eriko Miyawaki, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Hideyuki Harada, Takashi Sugino, Tetsuo Shimizu, Yasuhiro Gon, Toshiaki Takahashi. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. International Journal of Clinical Oncology 2021; 26(4) doi: 10.1007/s10147-020-01856-x
|
| 46 |
Kazutaka Hosoya, Daichi Fujimoto, Hayato Kawachi, Yuki Sato, Mariko Kogo, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Shinya Hiraoka, Masaki Kokubo, Keisuke Tomii. Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology 2019; 84(2) doi: 10.1007/s00280-019-03885-4
|
| 47 |
Xabier Mielgo-Rubio, Federico Rojo, Laura Mezquita-Pérez, Francesc Casas, Amadeo Wals, Manel Juan, Carlos Aguado, Javier Garde-Noguera, David Vicente, Felipe Couñago. Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck. World Journal of Clinical Oncology 2020; 11(11): 898-917 doi: 10.5306/wjco.v11.i11.898
|
| 48 |
Nikolaos F Pistamaltzian, Vassilis Georgoulias, Athanasios Kotsakis. The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. Expert Review of Respiratory Medicine 2019; 13(5) doi: 10.1080/17476348.2019.1593828
|
| 49 |
Christoph Grohmann, Francesca Walker, Mark Devlin, Meng-Xiao Luo, Anderly C. Chüeh, Judy Doherty, François Vaillant, Gwo-Yaw Ho, Matthew J. Wakefield, Clare E. Weeden, Alvin Kamili, Jayne Murray, Sela T. Po’uha, Janet Weinstock, Serena R. Kane, Maree C. Faux, Esmee Broekhuizen, Ye Zheng, Kristy Shield-Artin, Nadia J. Kershaw, Chin Wee Tan, Helen M. Witchard, Gregor Ebert, Susan A. Charman, Ian Street, Maria Kavallaris, Michelle Haber, Jamie I. Fletcher, Marie-Liesse Asselin-Labat, Clare L. Scott, Jane E. Visvader, Geoffrey J. Lindeman, Keith G. Watson, Antony W. Burgess, Guillaume Lessene. Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors. Cell Death & Disease 2021; 12(3) doi: 10.1038/s41419-020-03269-0
|
| 50 |
Dennis Jun Jie Poon, Li Min Tay, Dean Ho, Melvin Lee Kiang Chua, Edward Kai-Hua Chow, Eugenia Li Ling Yeo. Improving the therapeutic ratio of radiotherapy against radioresistant cancers: Leveraging on novel artificial intelligence-based approaches for drug combination discovery. Cancer Letters 2021; 511 doi: 10.1016/j.canlet.2021.04.019
|
| 51 |
Nicoly Marques de Castro, Fernando Moura, Aline Lury Hada, Diogo Garcia, Elivane da Silva Victor, Gustavo Schvartsman, Leonardo Carvalho, Milena Lourenço Coleta Fernandes, Rodrigo de Souza Martins, Elaine Ferreira da Silva, Sarah Silva Mello Batista dos Santos, Letícia Taniwaki, Patrícia Taranto, Janaina Pontes, Juliana Rodrigues Beal, Ana Carolina Pereira Dutra, João Bosco de Oliveira, Sérgio Eduardo Alonso Araujo, Pedro Luiz Serrano Usón. Prognostic value of programmed cell death ligand 1 (PD-L1) expression in patients with stage III non-small cell lung cancer under different treatment types: a retrospective study. einstein (São Paulo) 2024; 22 doi: 10.31744/einstein_journal/2024AO0575
|
| 52 |
Adithya Balasubramanian, James Onggo, Ashray Gunjur, Thomas John, Sagun Parakh. Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non–small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results. Clinical Lung Cancer 2021; 22(2) doi: 10.1016/j.cllc.2020.10.023
|
| 53 |
Jihane Boustani, Elodie Lauret Marie Joseph, Etienne Martin, Salim Benhmida, Benoit Lecoester, Florent Tochet, Céline Mirjolet, Cédric Chevalier, David Thibouw, Noémie Vulquin, Stéphanie Servagi, Xushan Sun, Olivier Adotévi. Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood. BMC Immunology 2021; 22(1) doi: 10.1186/s12865-021-00429-5
|
| 54 |
Faizan Haider Khan, Malik Johid Reza, Yusra Fatima Shao, Ahmad Perwez, Honey Zahra, Afshin Dowlati, Ata Abbas. Role of exosomes in lung cancer: A comprehensive insight from immunomodulation to theragnostic applications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022; 1877(5) doi: 10.1016/j.bbcan.2022.188776
|
| 55 |
Seema Kumari, Deme Karikios, Roland Yeghiaian‐Alvandi, Peter Flynn, Lucy Morgan, Lisa Kay, Pei Ding. Treatment patterns and long‐term survival outcomes for patients with stage III non‐small cell lung cancer: A retrospective study. Asia-Pacific Journal of Clinical Oncology 2024; 20(1) doi: 10.1111/ajco.13937
|
| 56 |
Salma K. Jabbour, Ki Hyeong Lee, Nikolaj Frost, Valeriy Breder, Dariusz M. Kowalski, Theodore Pollock, Evgeny Levchenko, Noemi Reguart, Alex Martinez-Marti, Baerin Houghton, Jean-Baptiste Paoli, Sufia Safina, Keunchil Park, Takefumi Komiya, Amy Sanford, Vishal Boolell, Hong Liu, Ayman Samkari, Steven M. Keller, Martin Reck. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer. JAMA Oncology 2021; 7(9) doi: 10.1001/jamaoncol.2021.2301
|
| 57 |
Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study). Lung Cancer 2020; 146 doi: 10.1016/j.lungcan.2020.05.033
|
| 58 |
N. V. Marinichenko, K. K. Laktionov, A. V. Nazarenko, E. V. Reutova, Merab S. Ardzinba, V. L. Utkina, T. N. Borisova, A. A. Fedorova, Milada S. Ardzinba. Combination of chemoradiation therapy with immunotherapy in the treatment of patients with inoperable stage III non-small cell lung cancer. Meditsinskiy sovet = Medical Council 2020; (20) doi: 10.21518/2079-701X-2020-20-209-214
|
| 59 |
Scott J. Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H. Lee, Maike de Wit, Byoung C. Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young-Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz-Ares, Javier de Castro Carpeño, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. New England Journal of Medicine 2017; 377(20) doi: 10.1056/NEJMoa1709937
|
| 60 |
Julian Taugner, Lukas Käsmann, Chukwuka Eze, Alexander Rühle, Amanda Tufman, Niels Reinmuth, Thomas Duell, Claus Belka, Farkhad Manapov. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Investigational New Drugs 2021; 39(4) doi: 10.1007/s10637-021-01091-9
|
| 61 |
Nareenart Iemwimangsa, Dulyathat Anantaya, Songporn Oranratnachai, Thanaporn Thamrongjirapat, Putthapoom Lumjiaktase, View-Hune Teoh, Khantong Khiewngam, Nanamon Monnamo, Pimtip Sanvarinda, Pimpin Incharoen, Angkana Charoenyingwattan, Insee Sensorn, Thitiya Dejthevaporn, Ekaphop Sirachainan, Wasun Chantratita, Thanyanan Reungwetwattana, Narumol Trachu. Dynamic changes in immune repertoire profiles in patients with stage III unresectable non-small cell lung cancer during consolidation treatment with immunotherapy. BMC Cancer 2025; 25(1) doi: 10.1186/s12885-025-13716-w
|
| 62 |
Oisín Bugter, Dirk L.P. van Iwaarden, Emilie A.C. Dronkers, Martine J. de Herdt, Marjan H. Wieringa, Gerda M. Verduijn, Marc A.M. Mureau, Ivo ten Hove, Esther van Meerten, José A. Hardillo, Robert J. Baatenburg de Jong. Survival of patients with head and neck cancer with metachronous multiple primary tumors is surprisingly favorable. Head & Neck 2019; 41(6) doi: 10.1002/hed.25595
|
| 63 |
Jia-Xue Yang, Wei-Hua Zhang, Jin-Ju Lei, Chun Cheng, Meng Yu, Ping Zhang, Yi Sang. SOHLH2-RAD54L axis induces radioresistance by promoting homologous recombination repair in non-small cell lung cancer. Cell Death Discovery 2026; 12(1) doi: 10.1038/s41420-025-02924-9
|
| 64 |
Rachana Choudhary, Neetu Das, Bhuneshwari Nayak, Rachana Tiwari, Ananya Malekar, Vaibhavi Sahare. Advancements in Drug Discovery Techniques for Cancer Treatment: Clinical Progress and Future Directions. Current Drug Discovery Technologies 2026; 23(2) doi: 10.2174/0115701638365059250707070424
|
| 65 |
Jiaqi Han, Kun Tian, Jiangping Yang, Youling Gong. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis. Lung Cancer 2020; 146 doi: 10.1016/j.lungcan.2020.05.011
|
| 66 |
Amaiyya Agrawal, Sankha Bhattacharya. Cutting-edge Nanotechnological Approaches for Lung Cancer Therapy. Current Drug Research Reviews 2022; 14(3) doi: 10.2174/2589977514666220418085658
|
| 67 |
Jayasheela S Hiremath, AHM Viswanath Swamy, Pooja Mahajan, Tejashree Sridhar, Sudhanshu Shukla. A comprehensive review of clinical outcomes and safety profile of durvalumab in non-small cell lung cancer. MGM Journal of Medical Sciences 2024; 11(1) doi: 10.4103/mgmj.mgmj_275_23
|
| 68 |
Anjali K. Pahuja, Kundan Singh Chufal, Irfan Ahmad, Ram Bajpai, Rajpal Singh, Rahul Lal Chowdhary, Maithili Sharma. Identifying Prognostic Groups Using Machine Learning Tools in Patients Undergoing Chemoradiation for Inoperable Locally Advanced Nonsmall Cell Lung Carcinoma. Asian Journal of Oncology 2019; 5 doi: 10.1055/s-0039-3401437
|
| 69 |
Yuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, Yukari Uemura, Eisaku Miyauchi, Takaya Yamamoto, Hiroshi Mayahara, Akito Hata, Hidetsugu Nakayama, Satoshi Tanaka, Junji Uchida, Kazuhiro Usui, Tatsuya Toyoda, Motohiro Tamiya, Masahiro Morimoto, Yuko Oya, Takeshi Kodaira, Keiichi Jingu, Hisatoshi Sugiura. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study. Clinical and Translational Radiation Oncology 2022; 37 doi: 10.1016/j.ctro.2022.08.010
|
| 70 |
Ming Zhang, Libing Sun, Yi Ru, Shasha Zhang, Junjun Miao, Pengda Guo, Jinghuan Lv, Feng Guo, Biao Liu. A risk score system based on DNA methylation levels and a nomogram survival model for lung squamous cell carcinoma. International Journal of Molecular Medicine 2020; 46(1) doi: 10.3892/ijmm.2020.4590
|
| 71 |
David Waterhouse, Candice Yong, Andrew Frankart, Lance Brannman, Tiernan Mulrooney, Nicholas Robert, Kathleen M Aguilar, Juliet Ndukum, Ion Cotarla. Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting. Future Oncology 2023; 19(28) doi: 10.2217/fon-2023-0117
|
| 72 |
Corinne Faivre-Finn, David R. Spigel, Suresh Senan, Corey Langer, Bradford A. Perez, Mustafa Özgüroğlu, Davey Daniel, Augusto Villegas, David Vicente, Rina Hui, Shuji Murakami, Luis Paz-Ares, Helen Broadhurst, Catherine Wadsworth, Phillip A. Dennis, Scott J. Antonia. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer 2021; 151 doi: 10.1016/j.lungcan.2020.11.024
|
| 73 |
James Kavanaugh, Geoffrey Hugo, Cliff G. Robinson, Michael C. Roach. Anatomical Adaptation—Early Clinical Evidence of Benefit and Future Needs in Lung Cancer. Seminars in Radiation Oncology 2019; 29(3) doi: 10.1016/j.semradonc.2019.02.009
|
| 74 |
Hong Zhu, Yi Xu, Huiquan Gao, Xingwen Fan, Ming Fan, Kuaile Zhao, Huanjun Yang, Zhengfei Zhu, Kailiang Wu. Long‐term outcome of definitive radiotherapy for locally advanced non‐small cell lung cancer: A real‐world single‐center study in the pre‐durvalumab era. Cancer Medicine 2024; 13(15) doi: 10.1002/cam4.70051
|
| 75 |
Antoine Desilets, Félix Blanc-Durand, Sally Lau, Taiki Hakozaki, Rui Kitadai, Julie Malo, Wiam Belkaid, Corentin Richard, Meriem Messaoudene, Lena Cvetkovic, Suzanne Kazandjian, Mustapha Tehfe, Marie Florescu, Kevin Jao, Nathalie Daaboul, Scott Owen, Benjamin Shieh, Jason Agulnik, Victor Cohen, Chloé Charbonneau, Nicolas Marcoux, Normand Blais, Natasha B. Leighl, Penelope A. Bradbury, Geoffrey Liu, Frances A. Shepherd, Houda Bahig, Bertrand Routy, Adrian Sacher, Arielle Elkrief. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study. European Journal of Cancer 2021; 142 doi: 10.1016/j.ejca.2020.10.008
|
| 76 |
Sanjay Popat, Neal Navani, Keith M. Kerr, Egbert F. Smit, Timothy J.P. Batchelor, Paul Van Schil, Suresh Senan, Fiona McDonald. Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach. The Oncologist 2021; 26(2) doi: 10.1002/onco.13586
|
| 77 |
Andrew J. Plodkowski, Jose Arimateia Batista Araujo-Filho, Cameron D.A. Simmers, Jeffrey Girshman, Micheal Raj, Junting Zheng, Andreas Rimner, Michelle S. Ginsberg. Pre-treatment CT imaging in stage IIIA lung cancer: Can we predict local recurrence after definitive chemoradiotherapy?. Clinical Imaging 2021; 69 doi: 10.1016/j.clinimag.2020.07.005
|
| 78 |
Xuchun Liu, Gengyun Sun. Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells. Oncology Letters 2017; 14(4) doi: 10.3892/ol.2017.6702
|
| 79 |
Jyoti D. Patel, Steven J. Chmura. Is immune checkpoint inhibition part of standard therapy for stage III non‐small cell lung cancer?. Cancer 2018; 124(14) doi: 10.1002/cncr.31557
|
| 80 |
Soomin Lee, Julip Jung, Helen Hong, Bong-Seog Kim. Prediction of Two-Year Recurrence-Free Survival in Operable NSCLC Patients Using Radiomic Features from Intra- and Size-Variant Peri-Tumoral Regions on Chest CT Images. Diagnostics 2022; 12(6) doi: 10.3390/diagnostics12061313
|
| 81 |
Yilin Yu, Zhiping Wang, Qunhao Zheng, Jiancheng Li. FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma. Aging 2021; 13(6) doi: 10.18632/aging.202625
|
| 82 |
Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, Jürgen Alt, Marlitt Horn, Stephan Eisenmann, Anke Schlenska-Lange, Philipp Schütt, Felix Steger, Wolfgang M. Brückl, Daniel C. Christoph. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer 2020; 150 doi: 10.1016/j.lungcan.2020.10.006
|
| 83 |
Beatrice T. B. Preti, Michael S. Sanatani, Daniel Breadner, Suganija Lakkunarajah, Carolyn Scott, Caroline Esmonde-White, Eric McArthur, George Rodrigues, Mitali Chaudhary, Adam Mutsaers, Robin Sachdeva, Mark D. Vincent. Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer. Current Oncology 2023; 30(8) doi: 10.3390/curroncol30080559
|
| 84 |
Rina Hui, Mustafa Özgüroğlu, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Jhanelle E Gray, Anna Rydén, Louis Viviers, Lynne Poole, Yiduo Zhang, Phillip A Dennis, Scott J Antonia. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. The Lancet Oncology 2019; 20(12) doi: 10.1016/S1470-2045(19)30519-4
|
| 85 |
Giulia Veronesi, Bernard Park, Robert Cerfolio, Mark Dylewski, Alpert Toker, Jacques P Fontaine, Wael C Hanna, Emanuela Morenghi, Pierluigi Novellis, Frank O Velez-Cubian, Marisa H Amaral, Elisa Dieci, Marco Alloisio, Eric M Toloza. Robotic resection of Stage III lung cancer: an international retrospective study†. European Journal of Cardio-Thoracic Surgery 2018; 54(5) doi: 10.1093/ejcts/ezy166
|
| 86 |
Bo-Yi Li, Yi Luo, Wen-Si Zhao, Lu Zhang, Han-Jing Zhou, Yu-Chun Zou, Tao Zhang. MicroRNA-210 negatively regulates the radiosensitivity of nasopharyngeal carcinoma cells. Molecular Medicine Reports 2017; 16(2) doi: 10.3892/mmr.2017.6694
|
| 87 |
Shubing Jia, Jian Chen, Ningyi Ma, Jingfang Zhao, Jingfang Mao, Guoliang Jiang, Jiade Lu, Kailiang Wu. Adaptive carbon ion radiotherapy for locally advanced non‐small cell lung cancer: Organ‐sparing potential and target coverage. Medical Physics 2022; 49(6) doi: 10.1002/mp.15563
|
| 88 |
Meghan J. Mooradian, Ling Cai, Alice Wang, Yao Qiao, Pratibha Chander, Ryan M. Whitaker. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer. JAMA Network Open 2024; 7(4) doi: 10.1001/jamanetworkopen.2024.7542
|
| 89 |
RUI ZHOU, JIANYANG XU, LINGWEI WANG, JIANXIN LI. LncRNA PRRT3-AS1 exerts oncogenic effects on nonsmall cell lung cancer by targeting microRNA-507/homeobox B5 axis. Oncology Research 2021; 29(6) doi: 10.32604/or.2022.026236
|
| 90 |
Wenjie Wu, Siyu Zhu, Yonghui Wu, Lu Dai, Jian Zhao, Zeyong Jiang. Long intergenic non-protein-coding RNA 1547 acts as a competing endogenous RNA and exerts cancer-promoting activity in non-small cell lung cancer by targeting the microRNA-195-5p/ homeobox C8 axis. Heliyon 2023; 9(8) doi: 10.1016/j.heliyon.2023.e18015
|
| 91 |
Ion Cotarla, Marnie L. Boron, Shawna L. Cullen, Daryl S. Spinner, Eric C. Faulkner, Marissa C. Carroll, Surbhi Shah, Adam Yagui-Beltran. Treatment Decision Drivers in Stage III Non–Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States. JCO Oncology Practice 2020; 16(10) doi: 10.1200/JOP.19.00781
|
| 92 |
Saber A. Amin, Chi Lin, Apar K. Ganti, Weining Ken Zhen, Chi Zhang. Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy. Frontiers in Oncology 2026; 15 doi: 10.3389/fonc.2025.1652522
|
| 93 |
Andrew Hope, Maikel Verduin, Thomas J Dilling, Ananya Choudhury, Rianne Fijten, Leonard Wee, Hugo JWL Aerts, Issam El Naqa, Ross Mitchell, Marc Vooijs, Andre Dekker, Dirk de Ruysscher, Alberto Traverso. Artificial Intelligence Applications to Improve the Treatment of Locally Advanced Non-Small Cell Lung Cancers. Cancers 2021; 13(10) doi: 10.3390/cancers13102382
|
| 94 |
Joanna Jagieła, Piotr Bartnicki, Jacek Rysz. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 2021; 22(9) doi: 10.3390/ijms22094618
|
| 95 |
Greta Alì, Rossella Bruno, Mauro Savino, Riccardo Giannini, Serena Pelliccioni, Maura Menghi, Laura Boldrini, Agnese Proietti, Antonio Chella, Alessandro Ribechini, Gabriella Fontanini. Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?. Archives of Pathology & Laboratory Medicine 2018; 142(4) doi: 10.5858/arpa.2017-0135-RA
|
| 96 |
Ana Peláez Bejarano, Olalla Montero Pérez. Successful treatment with durvalumab: A case report and review. Journal of Cancer Research and Therapeutics 2023; 19(2) doi: 10.4103/jcrt.jcrt_1430_21
|
| 97 |
Jing Zhang, Xintong Zhang, Xiaoting Zhao, Mei Jiang, Meng Gu, Ziyu Wang, Wentao Yue. DKK1 promotes migration and invasion of non–small cell lung cancer via β-catenin signaling pathway. Tumor Biology 2017; 39(7) doi: 10.1177/1010428317703820
|
| 98 |
Yan‐Yan Li, Chun Yang, Pingting Zhou, Shijie Zhang, Yuan Yao, Dong Li. Genome‐scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma. Journal of Cellular Biochemistry 2018; 119(11) doi: 10.1002/jcb.27144
|
| 99 |
Yin Shi, Rui Pei, Shao Liu. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.833773
|
| 100 |
Yoshiaki Amino, Satoru Kitazono, Shinya Uematsu, Tsukasa Hasegawa, Takahiro Yoshizawa, Ken Uchibori, Noriko Yanagitani, Atsushi Horiike, Takeshi Horai, Kazuo Kasahara, Makoto Nishio. Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC. International Journal of Clinical Oncology 2020; 25(1) doi: 10.1007/s10147-019-01537-4
|
| 101 |
Sarah Sharman Moser, Shira Yaari, Lior Apter, Bernadette Poellinger, Milan Rheenen, Ashwini Arunachalam, Gabriel Chodick, Moshe Hoshen, Sivan Gazit, Nava Siegelmann-Danieli. Mapping the patient journey and treatment patterns in early-stage (stage I-III) non-small cell lung cancer. Cancer Epidemiology 2024; 93 doi: 10.1016/j.canep.2024.102678
|
| 102 |
Paola Maria Medusa , Marina Gilli, Luca Notizia, Raffaella Pagliaro, Nicola Carro, Alessandro Moriello, Vito D'Agnano, Andrea Bianco, Fabio Perrotta, Fabiana Vitiello. Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report. Monaldi Archives for Chest Disease 2022; doi: 10.4081/monaldi.2022.2440
|
| 103 |
Kimberly Geiger, Markus Joerger, Max Roessler, Karina Hettwer, Christoph Ritter, Kirsten Simon, Steffen Uhlig, Stefan Holdenrieder. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy. Tumor Biology 2024; 46(s1) doi: 10.3233/TUB-230014
|
| 104 |
Mohammadhadi Khorrami, Prantesh Jain, Kaustav Bera, Mehdi Alilou, Rajat Thawani, Pradnya Patil, Usman Ahmad, Sudish Murthy, Kevin Stephans, Pinfu Fu, Vamsidhar Velcheti, Anant Madabhushi. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer 2019; 135 doi: 10.1016/j.lungcan.2019.06.020
|
| 105 |
K. Franks, D. Smith, P. Shaw, G.L. Banna, M. Cominos, T. Talbot, B.T. Blak, L. Lindqvist-Brown, M. Ahmed. CODAK: Real-World Clinical Outcomes of Patients With Unresectable, Stage III Non–Small Cell Lung Cancer Treated With Durvalumab After Chemoradiotherapy in the United Kingdom. Clinical Oncology 2025; 48 doi: 10.1016/j.clon.2025.103949
|
| 106 |
Maura R. Vrabel, Jacob A. Schulman, Francis B. Gillam, Siena M. Mantooth, Khue G. Nguyen, David A. Zaharoff. Focal Cryo-Immunotherapy with Intratumoral IL-12 Prevents Recurrence of Large Murine Tumors. Cancers 2023; 15(8) doi: 10.3390/cancers15082210
|
| 107 |
Shantelle Smith, Daniel Sapkaroski, Margaret Brand, Anh Tran, John Zalcberg, Robert G. Stirling. Mapping the clinical care pathways for advanced stage non‐small cell lung cancer patients in Victoria: A retrospective cohort study of supportive and palliative care. Nursing & Health Sciences 2023; 25(3) doi: 10.1111/nhs.13044
|
| 108 |
Wan Ling Tan, Kevin L.M. Chua, Chia-Chi Lin, Victor H.F. Lee, Lye Mun Tho, Anthony W. Chan, Gwo Fuang Ho, Thanyanan Reungwetwattana, James C. Yang, Dong-Wan Kim, Ross A. Soo, Yong Chan Ahn, Hiroshi Onishi, Myung-Ju Ahn, Tony S.K. Mok, Daniel S.W. Tan, Fan Yang. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. Journal of Thoracic Oncology 2020; 15(3) doi: 10.1016/j.jtho.2019.10.022
|
| 109 |
David R. Spigel, Corinne Faivre-Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz-Ares, Johan F. Vansteenkiste, Marina C. Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Özgüroğlu, Ki H. Lee, Terufumi Kato, Maike de Wit, Takayasu Kurata, Martin Reck, Byoung C. Cho, Suresh Senan, Jarushka Naidoo, Helen Mann, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 2022; 40(12) doi: 10.1200/JCO.21.01308
|
| 110 |
Wang Jing, Ting Xu, Lirong Wu, Pablo B. Lopez, Clemens Grassberger, Susannah G. Ellsworth, Radhe Mohan, Brian P. Hobbs, George R. Blumenschein, Janet Tu, Mehmet Altan, Percy Lee, Zhongxing Liao, Steven H. Lin. Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clinical and Research Reports 2022; 3(9) doi: 10.1016/j.jtocrr.2022.100391
|
| 111 |
Yuan Zheng, Wei Zhu, Xinjie Huang, Dongqun Lin, Yu Lin. Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review. Open Life Sciences 2021; 16(1) doi: 10.1515/biol-2021-0083
|
| 112 |
Mumtaz V. Rojiani, Amyn M. Rojiani. Non-Small Cell Lung Cancer—Tumor Biology. Cancers 2024; 16(4) doi: 10.3390/cancers16040716
|
| 113 |
Ullas Batra, Kumar Prabhash, Jai Prakash Agarwal, Laleng Darlong, Anusheel Munshi, Prasanth Penumadu, Balamugesh Thangakunam, Abhishek Bansal. Clinical management of stage III non‐small cell lung cancer in India: An expert consensus statement. Asia-Pacific Journal of Clinical Oncology 2023; 19(6) doi: 10.1111/ajco.13938
|
| 114 |
Juliette Degens, D De Ruysscher, Ruud Houben, Bastiaan Kietselaer, Gerben Bootsma, Lizza Hendriks, Ellen Huijbers, Annemie Schols, Anne-Marie C Dingemans. Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study. BMJ Open 2020; 10(9) doi: 10.1136/bmjopen-2019-036492
|
| 115 |
Hongyu Zhou, Jun Xiao, Qi Cheng, Wen Wang, He Peng, Xiaojian Lin, Jiajun Chen, Xingya Wang. Metformin inhibits migration and epithelial-to-mesenchymal transition in non-small cell lung cancer cells through AMPK-mediated GDF15 induction. European Journal of Pharmacology 2024; 985 doi: 10.1016/j.ejphar.2024.177127
|
| 116 |
Priyanka Bobbili, Kellie Ryan, Maral DerSarkissian, Akanksha Dua, Christopher Yee, Mei Sheng Duh, Jorge E. Gomez, Jason Chia-Hsun Hsieh. Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer. PLOS ONE 2020; 15(3) doi: 10.1371/journal.pone.0230444
|
| 117 |
Kazumasa Ogawa, Yui Takahashi, Kyoko Murase, Shigeo Hanada, Hironori Uruga, Hisashi Takaya, Atsushi Miyamoto, Nasa Morokawa, Atsuko Kurosaki, Kazuma Kishi. Treatment outcome of patients with unresectable stage III non-small cell lung cancer and interstitial pneumonia. Respiratory Investigation 2019; 57(4) doi: 10.1016/j.resinv.2019.02.004
|
| 118 |
HongBo Su, GuanZhi Fan, Jin Huang, XueShan Qiu. LncRNA HOXC-AS3 promotes non-small-cell lung cancer growth and metastasis through upregulation of YBX1. Cell Death & Disease 2022; 13(4) doi: 10.1038/s41419-022-04723-x
|
| 119 |
Mingjun Xu, Yan Xu, Yingchun Man, Xuqin Xiang, Dexin Jia, Junzhu Dai, Weitong Gao, Ruqiong Wang, Bo An, Kaile Zhao, Jiaojiao Li, Bo Pan, Yan Yu. Real‐world effectiveness and safety of treatment strategies for unresectable, driver‐negative Stage III NSCLC: A retrospective multicentre study. International Journal of Cancer 2026; 158(4) doi: 10.1002/ijc.70162
|
| 120 |
Muhammet Ali BEYOGLU, Selim Şakir Erkmen GULHAN, Ayperi ÖZTÜRK, Leyla Nesrin ACAR, Mehmet ŞAHİN, Gokturk FİNDİK. The Survival Efficiency of Initial Surgical Treatment in Stage IIIa-N2 Positive Non-Small Cell Lung Cancer. Middle Black Sea Journal of Health Science 2021; 7(3) doi: 10.19127/mbsjohs.981036
|
| 121 |
Amanda M. Moore, Zohra Nooruddin, Kelly R. Reveles, Paromita Datta, Jennifer M. Whitehead, Kathleen Franklin, Munaf Alkadimi, Madison H. Williams, Ryan A. Williams, Sarah Smith, Renee Reichelderfer, Ion Cotarla, Lance Brannman, Andrew Frankart, Tiernan Mulrooney, Kristin Hsieh, Daniel J. Simmons, Xavier Jones, Christopher R. Frei. Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study. Current Oncology 2023; 30(9) doi: 10.3390/curroncol30090611
|
| 122 |
Brett H. Diamond, Neel Belani, Rebecca Masel, Kathryn DeCarli, Thomas DiPetrillo, Jaroslaw T. Hepel, Christopher G. Azzoli, Humera Khurshid, Abbas Abbas, Paul P. Koffer. Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab. Advances in Radiation Oncology 2023; 8(2) doi: 10.1016/j.adro.2022.101130
|
| 123 |
Aswin Ravi, Sushmita Pathy, Supriya Mallick, Prabhat S. Malik, Sunil Kumar, Rajeev Kumar. Pattern of care in locally advanced non-small cell lung cancer: A tertiary care experience from India. Lung India 2025; 42(6) doi: 10.4103/lungindia.lungindia_70_25
|
| 124 |
Julian Taugner, Lukas Käsmann, Chukwuka Eze, Amanda Tufman, Niels Reinmuth, Thomas Duell, Claus Belka, Farkhad Manapov. Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting. Cancers 2021; 13(7) doi: 10.3390/cancers13071613
|
| 125 |
Hanieh Abedian Kalkhoran, Marjon V. Verschueren, Bas J.M. Peters, Ewoudt M.W. van de Garde, Egbert F. Smit, Stefan Bohringer, Danielle Cohen, Judith L. Gulikers, Henk Codrington, Henk-Jan Guchelaar, Loes E. Visser, Juliëtte Zwaveling. Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?. Clinical Lung Cancer 2025; 26(7) doi: 10.1016/j.cllc.2025.07.009
|
| 126 |
Yatong Zhang, Yumei Tian, Li Zheng, Xuelin Sun, Zinan Zhao, Yujing Zheng, Jinhui Tian. Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1103927
|
| 127 |
Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung-Sik Hwang, Chang-Min Choi. Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. Cancer Research and Treatment 2023; 55(1) doi: 10.4143/crt.2022.264
|
| 128 |
Dae-Ho Choi, Miso Kim, Young Saing Kim, Keon Uk Park, Jang Ho Cho, Hongsik Kim, Ki Hyeong Lee, Heejoon Ahn, Il-Hwan Kim, Kyung-Hee Lee, Gyeong-Won Lee, Seong Yoon Yi, Beung chul Ahn, Min-Young Lee, Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Myung-Ju Ahn. Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18. JTO Clinical and Research Reports 2024; 5(12) doi: 10.1016/j.jtocrr.2024.100734
|
| 129 |
Angela Sardaro, Fiona McDonald, Lilia Bardoscia, Konstantin Lavrenkov, Shalini Singh, Sue Ashley, Daphne Traish, Cristina Ferrari, Icro Meattini, Artor Niccoli Asabella, Michael Brada. Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.594590
|
| 130 |
Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo, Akito Hata. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Radiation Oncology 2022; 17(1) doi: 10.1186/s13014-021-01979-z
|
| 131 |
Martin Wilhelm. Durvalumab nach einer Radiochemotherapie ist beim NSCLC im Stadium III derzeit die vielversprechendste Therapie. Strahlentherapie und Onkologie 2019; 195(7) doi: 10.1007/s00066-019-01456-3
|
| 132 |
Scott J. Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki H. Lee, Maike de Wit, Byoung C. Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young-Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz-Ares, Javier de Castro Carpeño, Corinne Faivre-Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine 2018; 379(24) doi: 10.1056/NEJMoa1809697
|
| 133 |
Carsten Brink, Uffe Bernchou, Anders Bertelsen, Olfred Hansen, Tine Schytte, Jacob v.B. Hjelmborg, Lois Holloway, Marcel van Herk, Corinne Johnson-Hart, Gareth J. Price, Marianne C. Aznar, Alan McWilliam, Corinne Faivre-Finn, Christian R. Hansen. Causal relation between heart irradiation and survival of lung cancer patients after radiotherapy. Radiotherapy and Oncology 2022; 172 doi: 10.1016/j.radonc.2022.05.002
|
| 134 |
Eriko Miyawaki, Hirotsugu Kenmotsu, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Nobuyuki Yamamoto, Tomoya Kawaguchi, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date. Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09441-3
|
| 135 |
Priyanka Bobbili, Kellie Ryan, Mei S Duh, Akanksha Dua, Ancilla W Fernandes, Melissa Pavilack, Jorge E Gomez. Treatment Patterns and Overall Survival among Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer. Future Oncology 2019; 15(29) doi: 10.2217/fon-2019-0282
|
| 136 |
G. Daniel Grass, Arash O. Naghavi, Yazan A. Abuodeh, Bradford A. Perez, Thomas J. Dilling. Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer 2019; 20(1) doi: 10.1016/j.cllc.2018.08.009
|
| 137 |
Yuko Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, Katsuya Hirano, Atsushi Horiike, Miyako Satouchi, Shinobu Hosokawa, Ryotaro Morinaga, Kazutoshi Komiya, Koji Inoue, Yuka Fujita, Ryo Toyozawa, Tomoki Kimura, Kosuke Takahashi, Kazuo Nishikawa, Junji Kishimoto, Yoichi Nakanishi, Isamu Okamoto. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer. Lung Cancer 2018; 125 doi: 10.1016/j.lungcan.2018.09.014
|
| 138 |
Howard West, Xiaohan Hu, Su Zhang, Yan Song, Diana Chirovsky, Chi Gao, Ariel Lerner, Anya Jiang, James Signorovitch, Ayman Samkari. Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data. Clinical Lung Cancer 2023; 24(3) doi: 10.1016/j.cllc.2022.12.005
|
| 139 |
Duygu Sezen, Hampartsoum B. Barsoumian, Kewen He, Yun Hu, Qi Wang, Chike O. Abana, Nahum Puebla-Osorio, Ethan Y. Hsu, Mark Wasley, Fatemeh Masrorpour, Jing Wang, Maria Angelica Cortez, James W. Welsh. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.984318
|
| 140 |
Joanna Pancewicz, Wiesława Ewa Niklińska, Adrian Chlanda. Flake Graphene-Based Nanomaterial Approach for Triggering a Ferroptosis as an Attractive Theranostic Outlook for Tackling Non-Small Lung Cancer: A Mini Review. Materials 2022; 15(10) doi: 10.3390/ma15103456
|
| 141 |
Corinne Faivre-Finn, David Vicente, Takayasu Kurata, David Planchard, Luis Paz-Ares, Johan F. Vansteenkiste, David R. Spigel, Marina C. Garassino, Martin Reck, Suresh Senan, Jarushka Naidoo, Andreas Rimner, Yi-Long Wu, Jhanelle E. Gray, Mustafa Özgüroğlu, Ki H. Lee, Byoung C. Cho, Terufumi Kato, Maike de Wit, Michael Newton, Lu Wang, Piruntha Thiyagarajah, Scott J. Antonia. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. Journal of Thoracic Oncology 2021; 16(5) doi: 10.1016/j.jtho.2020.12.015
|
| 142 |
Ayomide Adeyemi Abe, Mpumelelo Nyathi. Lung Cancer Diagnosis From Computed Tomography Images Using Deep Learning Algorithms With Random Pixel Swap Data Augmentation: Algorithm Development and Validation Study. JMIR Bioinformatics and Biotechnology 2025; 6 doi: 10.2196/68848
|
| 143 |
Ida Kappel Buhl, Eric Santoni-Rugiu, Jesper Ravn, Anker Hansen, Ib Jarle Christensen, Thomas Jensen, Bruce Pratt, Jon Askaa, Peter Buhl Jensen, Steen Knudsen, Jens Benn Sørensen, Aamir Ahmad. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts. PLOS ONE 2018; 13(3) doi: 10.1371/journal.pone.0194609
|
| 144 |
Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, Megumi Inaba, Ryosuke Ochiai, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Yosuke Miyamoto, Toshihide Yokoyama, Chiaki Matsumoto, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki. Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study). Therapeutic Advances in Medical Oncology 2022; 14 doi: 10.1177/17588359221116603
|
| 145 |
Martin J Edelman. The PACIFIC Trial—Where Do We Go from Here in Immunotherapy for Non-small Cell Lung Cancer?. Oncology & Hematology Review (US) 2018; 14(2) doi: 10.17925/OHR.2018.14.2.65
|
| 146 |
Diem Vuong, Marta Bogowicz, Leonard Wee, Oliver Riesterer, Eugenia Vlaskou Badra, Louisa Abigail D’Cruz, Panagiotis Balermpas, Janita E. van Timmeren, Simon Burgermeister, André Dekker, Dirk De Ruysscher, Jan Unkelbach, Sandra Thierstein, Eric I. Eboulet, Solange Peters, Miklos Pless, Matthias Guckenberger, Stephanie Tanadini-Lang. Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-00239-0
|
| 147 |
Narjust Duma, Rafael Santana-Davila, Julian R. Molina. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings 2019; 94(8) doi: 10.1016/j.mayocp.2019.01.013
|
| 148 |
A.A. Abe, M. Nyathi, A.A. Okunade, W. Pilloy, B. Kgole, N. Nyakale. A robust deep learning algorithm for lung cancer detection from computed tomography images. Intelligence-Based Medicine 2025; 11 doi: 10.1016/j.ibmed.2025.100203
|
| 149 |
M. F. Mridha, Akibur Rahman Prodeep, A. S. M. Morshedul Hoque, Md. Rashedul Islam, Aklima Akter Lima, Muhammad Mohsin Kabir, Md. Abdul Hamid, Yutaka Watanobe, Rafael Morales. A Comprehensive Survey on the Progress, Process, and Challenges of Lung Cancer Detection and Classification. Journal of Healthcare Engineering 2022; 2022 doi: 10.1155/2022/5905230
|
| 150 |
YANG ZHANG, LIXIA MA, TINGTING ZHANG, PEIDONG LI, JIABIN XU, ZHUO WANG. Long Noncoding RNA TFAP2A-AS1 Exerts Promotive Effects in Non-Small Cell Lung Cancer Progression Via Controlling the microRNA-548a-3p/CDK4 axis as a Competitive Endogenous RNA. Oncology Research 2021; 29(2) doi: 10.32604/or.2022.03563
|
| 151 |
Aditya Juloori, Everett E. Vokes. Beyond PACIFIC: Uncharted Waters. Journal of Thoracic Oncology 2021; 16(5) doi: 10.1016/j.jtho.2021.02.006
|
| 152 |
Lygia Bertalha Yaegashi, Camila Machado Baldavira, Tabatha Gutierrez Prieto, Juliana Machado-Rugolo, Ana Paula Pereira Velosa, Lizandre Keren Ramos da Silveira, Aline Assato, Alexandre Muxfeldt Ab’Saber, Roberto Falzoni, Teresa Takagaki, Pedro Leme Silva, Walcy Rosolia Teodoro, Vera Luiza Capelozzi. In Situ Overexpression of Matricellular Mechanical Proteins Demands Functional Immune Signature and Mitigates Non-Small Cell Lung Cancer Progression. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.714230
|
| 153 |
Jyoti D. Patel, Ju-Whei Lee, David P. Carbone, Henry Wagner, Anil Shanker, Maria Teresa P. de Aquino, Leora Horn, Melissa L. Johnson, David E. Gerber, Jane Jijun Liu, Millie S. Das, Mohammed Ali Al-Nsour, Christopher S.R. Dakhil, Suresh Ramalingam, Joan H. Schiller. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clinical Lung Cancer 2020; 21(6) doi: 10.1016/j.cllc.2020.06.007
|
| 154 |
Wenxin Ding, Jing Liang, Chaoying Chen, Jingsheng Zhao, Chaojiu Xu, Jinhua Zhang, Hao Zhou, Honghua Wu, Jian Long, Quan Zuo, Zhi Yang. Omission of clinical target volume in radiotherapy for unresectable stage III non-small cell lung cancer: a propensity score matching analysis. Annals of Medicine 2026; 58(1) doi: 10.1080/07853890.2026.2650866
|
| 155 |
Suzhen Wang, Huai‐Xin Xing, Jianbin Li, Ying‐Jie Zhang, Ting‐Yong Fan, Shuang‐Hu Yuan, Xu‐Dong Hu, Min Xu. Correlation of displacement of mediastinal metastatic lymph nodes with adjacent organs in non‐small cell lung cancer on four‐dimensional computed tomography. Precision Radiation Oncology 2019; 3(2) doi: 10.1002/pro6.64
|
| 156 |
Alice Spencer, Jenna Williams, Robert Samuel, Ian S. Boon, Katy Clarke, Pooja Jain. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre. Cancer Treatment and Research Communications 2021; 29 doi: 10.1016/j.ctarc.2021.100460
|
| 157 |
Juliana Matiello, Alan Dal Pra, Laise Zardo, Ricardo Silva, Danilo C Berton. Impacts of post‐radiotherapy lymphocyte count on progression‐free and overall survival in patients with stage III lung cancer. Thoracic Cancer 2020; 11(11) doi: 10.1111/1759-7714.13621
|
| 158 |
Ana Gómez Rueda, Álvaro Taus, Rosa Álvarez Álvarez, Reyes Bernabé-Caro, Luis Chara, Marta López-Brea, Laia Vilà, Maria Ángeles Sala González, Anabel del Barrio Díaz Aldagalán, Beatriz Esteban Herrera, Rafael López Castro, Ruth Álvarez Cabellos, Marta Doménech, Sandra Falagan, Alberto Moreno Vega, Carlos Aguado, Andrés Barba, Maria Teresa Delgado Ureña, Dolores Isla, Lorena Bellido Hernández, José Luis Fírvida Pérez, Óscar Juan-Vidal, Bartomeu Massutí, Xabier Mielgo-Rubio, Ana Laura Ortega, Silvia Catot, Manuel Dómine, Corina Escoín-Pérez, Francisco García Navalón, Ignacio Gil-Bazo, Silvia Muñoz, Delvys Rodríguez-Abreu, Rosa María Villatoro Roldán, Guillermo Alonso-Jáudenes Curbera, Luis León-Mateos, Airam Padilla, Alfredo Paredes Lario, José Miguel Sánchez-Torres, Pilar Garrido. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical and Translational Oncology 2024; 26(7) doi: 10.1007/s12094-024-03404-9
|
| 159 |
Yuting Zhan, Hongjing Zang, Juan Feng, Junmi Lu, Lingjiao Chen, Songqing Fan. Long non-coding RNAs associated with non-small cell lung cancer. Oncotarget 2017; 8(40) doi: 10.18632/oncotarget.20088
|
| 160 |
Wei Xiao, Lan Wang, John Howard, Ravindra Kolhe, Amyn M. Rojiani, Mumtaz V. Rojiani. TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC. Cancers 2019; 11(8) doi: 10.3390/cancers11081184
|
| 161 |
Georgios Chatzikonstantinou, Nikolaos Zamboglou, Dimos Baltas, Konstantinos Ferentinos, Dimitra Bon, Nikolaos Tselis. Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: A single-institute experience. Brachytherapy 2019; 18(6) doi: 10.1016/j.brachy.2019.08.001
|
| 162 |
Valentina Casalone, Chiara Lazzari, Elena Fassi, Vanesa Gregorc. Nutritional assessments and interventions in head and neck, esophageal, rectal and lung cancers undergoing anticancer treatments: a literature review. Frontiers in Oncology 2025; 15 doi: 10.3389/fonc.2025.1676305
|
| 163 |
Tomohiro Takehara, Tetsuo Tani, Hiroyuki Takiue, Ryo Takeshita, Arifumi Iwamaru, Tatsuya Yamamoto, Hidefumi Koh. Outcome of patients with lung cancer and severe psychiatric disorder admitted to a medical psychiatric unit. Molecular and Clinical Oncology 2020; doi: 10.3892/mco.2020.1974
|
| 164 |
Mauro Zukin1, Victor Gondim2, Andrea Kazumi Shimada3, Ellias Magalhães e Abreu Lima4, Clarissa Mathias5,6, Williams Fernandes Barra7, William Nassib William Junior8,9, Mônica Padoan2, Yuri Bittencourt3, Rosely Yamamura8, Carlos Eduardo Baston Silva10, Letícia de Jesus Rossato11, Caio de Almeida Monteiro1, Rafaela Gomes de Jesus12, Gustavo Gössling12, Ana Caroline Zimmer Gelatti13. Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120). Jornal Brasileiro de Pneumologia 2024; doi: 10.36416/1806-3756/e20240228
|
| 165 |
Qinhao Xu, Yana Qi, Xiaoyang Zhai, Feihu Chen, Yingfan Guo, Hui Zhu. Comparison of concurrent chemoradiotherapy followed by immunotherapy and induction chemoimmunotherapy followed by radiotherapy in unresectable stage III NSCLC: a retrospective cohort study. Future Oncology 2026; 22(7) doi: 10.1080/14796694.2026.2637732
|
| 166 |
Chiara Catania, Andrea Riccardo Filippi, Claudia Sangalli, Gaia Piperno, Marco Russano, Carlo Greco, Vieri Scotti, Claudia Proto, Chiara Bennati, Marzia Di Pietro Paolo, Angelo Platania, Emanuela Olmetto, Francesco Agustoni, Nazario Teodorani, Vincenzo Agbaje, Alessandro Russo. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group. Critical Reviews in Oncology/Hematology 2023; 190 doi: 10.1016/j.critrevonc.2023.104108
|
| 167 |
Jung Hyun Nam, Chang Dong Yeo, Chan Kwon Park, Sung Kyoung Kim, Ju Sang Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Kim, Sang Haak Lee, Hye Seon Kang. Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy. Thoracic Cancer 2023; 14(26) doi: 10.1111/1759-7714.15050
|
| 168 |
Hayato Kawachi, Motohiro Tamiya, Yuko Oya, Go Saito, Yoshihiko Taniguchi, Hirotaka Matsumoto, Yuki Sato, Taiichiro Otsuki, Hidekazu Suzuki, Yasushi Fukuda, Satoshi Tanaka, Yoko Tsukita, Junji Uchida, Yoshihiko Sakata, Yuki Nakatani, Ryota Shibaki, Daisuke Arai, Asuka Okada, Satoshi Hara, Koichi Takayama, Kazumi Nishino. Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005). Clinical Lung Cancer 2024; 25(7) doi: 10.1016/j.cllc.2024.07.014
|
| 169 |
Hisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, Tomonori Makiguchi, Megumi Inaba, Takeshi Honda, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Yasushi Fukuda, Masayuki Yasugi, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis. Therapeutic Advances in Medical Oncology 2022; 14 doi: 10.1177/17588359221142786
|
| 170 |
Yutaka Takahara, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Takashi Sakuma, Kazuaki Nishiki, Keisuke Nakase, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa, Shiro Mizuno. Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy. Thoracic Cancer 2022; 13(24) doi: 10.1111/1759-7714.14704
|
| 171 |
Abdul Rahman Jazieh, Huseyin Cem Onal, Daniel Shao-Weng Tan, Ross A. Soo, Kumar Prabhash, Amit Kumar, Reto Huggenberger, Byoung Chul Cho. Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study. Therapeutic Advances in Medical Oncology 2022; 14 doi: 10.1177/17588359221122720
|
| 172 |
Jie Zhang, Yang Hong, Liang Wang, Weiheng Hu, Guangming Tian, Di Wu, Yang Wang, Ling Dai, Ziran Zhang, Yue Yang, Jian Fang. Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.829054
|
| 173 |
Gokcen Ömeroğlu Şimşek, Pınar Çelik, James R. Jett. Airway Diseases. 2023; doi: 10.1007/978-3-031-22483-6_64-1
|
| 174 |
O. Ercelep, O. Alan, D. Sahin, T. A. Telli, H. Salva, T. B. Tuylu, N. A. Babacan, S. Kaya, F. Dane, T. Ones, H. Alkis, M. Adli, F. Yumuk. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer. Clinical and Translational Oncology 2019; 21(4) doi: 10.1007/s12094-018-1949-6
|
| 175 |
Tharcisio Citrangulo Tortelli, Rodrigo Esaki Tamura, Mara de Souza Junqueira, Janio da Silva Mororó, Silvina Odete Bustos, Renato Jose Mendonça Natalino, Shonagh Russell, Laurent Désaubry, Bryan Eric Strauss, Roger Chammas. Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells. Aging 2021; 13(18) doi: 10.18632/aging.203528
|
| 176 |
Fei Gao, Lin Jia, Jianjun Han, Yun Wang, Wenjuan Luo, Yan Zeng. Circ-ZNF124 downregulation inhibits non-small cell lung cancer progression partly by inactivating the Wnt/β-catenin signaling pathway via mediating the miR-498/YES1 axis. Anti-Cancer Drugs 2021; 32(3) doi: 10.1097/CAD.0000000000001014
|
| 177 |
Martina Vrankar, Karmen Stanic, Stasa Jelercic, Eva Ciric, Ana Lina Vodusek, Jasna But-Hadzic. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience. Radiology and Oncology 2021; 55(4) doi: 10.2478/raon-2021-0044
|
| 178 |
Jessica N. LeClair, Man Yee Merl, Michael Cohenuram, Darren Luon. Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab. Clinical Lung Cancer 2022; 23(1) doi: 10.1016/j.cllc.2021.08.006
|
| 179 |
Jhanelle E. Gray, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Byoung Chul Cho, David Planchard, Luis Paz-Ares, Corinne Faivre-Finn, Johan F. Vansteenkiste, David R. Spigel, Catherine Wadsworth, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu, Scott J. Antonia. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. Journal of Thoracic Oncology 2020; 15(2) doi: 10.1016/j.jtho.2019.10.002
|
| 180 |
Yufan Yang, Tao Zhang, Zongmei Zhou, Jun Liang, Dongfu Chen, Qinfu Feng, Zefen Xiao, Zhouguang Hui, Jima Lv, Lei Deng, Xin Wang, Wenqing Wang, Jianyang Wang, Wenyang Liu, Yirui Zhai, Jie Wang, Nan Bi, Luhua Wang. Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy. Thoracic Cancer 2022; 13(3) doi: 10.1111/1759-7714.14218
|
| 181 |
Saber A. Amin, Michael J. Baine, Ibur Rahman, Chi Lin. The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do Not Receive Chemoradiation. Journal of Immunotherapy 2023; 46(1) doi: 10.1097/CJI.0000000000000443
|
| 182 |
Giovanni Melillo, Vikram Chand, Alejandro Yovine, Ashok Gupta, Cristian Massacesi. Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. Advances in Therapy 2021; 38(6) doi: 10.1007/s12325-021-01675-0
|
| 183 |
Hsiu-Ying Hung, Yen-Han Tseng, Heng-Sheng Chao, Chao-Hua Chiu, Wen-Hu Hsu, Han-Shui Hsu, Yu-Chung Wu, Teh-Ying Chou, Chun-Ku Chen, Keng-Li Lan, Yi-Wei Chen, Yuan-Hung Wu, Yuh-Min Chen, Stephen Chun. Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer. PLOS ONE 2020; 15(10) doi: 10.1371/journal.pone.0236503
|
| 184 |
Leilei Wu, Bo Cheng, Xiaojiang Sun, Zhenshan Zhang, Jingjing Kang, Yun Chen, Qinghua Xu, Shuangyan Yang, Yujie Yan, Shengxiang Ren, Caicun Zhou, Yaping Xu. Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study. MedComm 2024; 5(3) doi: 10.1002/mco2.501
|
| 185 |
Ziyi Wang, Xinyu Zhang, Xuedong Zhang, Xuedong Jiang, Wenya Li. Long Noncoding RNA LINC01703 Exacerbates the Malignant Properties of Non-Small Cell Lung Cancer by Upregulating MACC1 in a MicroRNA-605-3p-Mediated Manner. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2021; 28(9) doi: 10.3727/096504021X16310057751016
|
| 186 |
Aykut Demirkıran, Murat Araz, Melek Karakurt Eryılmaz, Mustafa Karaağaç, Muhammed Muhiddin Er, Berrin Benli Yavuz, Mehmet Artaç. Prognostic Impact of the Systemic Immune-Inflammation Index According to Concurrent Chemotherapy Backbone in Stage III Non-Small Cell Lung Cancer. Current Oncology 2026; 33(7) doi: 10.3390/curroncol33070407
|
| 187 |
Ravi Rajaram, Arlene M. Correa, Ting Xu, Quynh-Nhu Nguyen, Mara B. Antonoff, David Rice, Reza Mehran, Jack Roth, Garrett Walsh, Stephen Swisher, Wayne L. Hofstetter, Ara Vaporciyan, Tina Cascone, Anne S. Tsao, Vassiliki A. Papadimitrakopoulou, Saumil Gandhi, Zhongxing Liao, Boris Sepesi. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clinical Lung Cancer 2020; 21(4) doi: 10.1016/j.cllc.2020.01.009
|
| 188 |
Ranee Mehra, Candice Yong, Brian Seal, Marjolijn van Keep, Angie Raad, Yiduo Zhang. Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective. Journal of the National Comprehensive Cancer Network 2021; 19(2) doi: 10.6004/jnccn.2020.7621
|
| 189 |
Fotis Nikolos, Christoforos Thomas, Igor Bado, Jan-Åke Gustafsson. ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response. Molecular Cancer Research 2018; 16(2) doi: 10.1158/1541-7786.MCR-17-0201
|
| 190 |
Chao Gao, Jiaqi Zhang, Xin Du, Xuehan Gao, Xiayao Diao, Ke Zhao, Yeye Chen, Shanqing Li. Prognostic determinants and functional role of PIK3C2G in stage IIb-IIIa lung adenocarcinoma: insights from clinical and molecular analyses. Frontiers in Oncology 2025; 14 doi: 10.3389/fonc.2024.1473437
|
| 191 |
Tadashi Sakaguchi, Kentaro Ito, Kazuki Furuhashi, Yuki Nakamura, Yuta Suzuki, Yoichi Nishii, Osamu Taguchi, Osamu Hataji. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria. Respiratory Investigation 2019; 57(5) doi: 10.1016/j.resinv.2019.03.011
|
| 192 |
J.B. Adizie, A. Khakwani, P. Beckett, N. Navani, D. West, I. Woolhouse, S.V. Harden. Stage III Non-small Cell Lung Cancer Management in England. Clinical Oncology 2019; 31(10) doi: 10.1016/j.clon.2019.07.020
|
| 193 |
S. Peters, E. Felip, U. Dafni, C. Belka, M. Guckenberger, A. Irigoyen, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martinez-Marti, A. Tufman, M. Lambrecht, N. Andratschke, A.C. Piguet, M. Kassapian, H. Roschitzki-Voser, M. Rabaglio-Poretti, R.A. Stahel, J. Vansteenkiste, D. De Ruysscher. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial. Lung Cancer 2019; 133 doi: 10.1016/j.lungcan.2019.05.001
|
| 194 |
Patrizio Armeni, Ludovica Borsoi, Giulia Fornaro, Claudio Jommi, Francesco Grossi, Francesco Costa. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service. Clinical Therapeutics 2020; 42(5) doi: 10.1016/j.clinthera.2020.03.012
|
| 195 |
Hongwei Liu, Qianqian Wang, Wanying Lan, Duanya Liu, Jiangang Huang, Jie Yao. Radiosensitization effect of quinoline-indole-schiff base derivative 10E on non-small cell lung cancer cells in vitro and in tumor xenografts. Investigational New Drugs 2024; 42(4) doi: 10.1007/s10637-024-01451-1
|
| 196 |
Nicolas Girard, Jair Bar, Pilar Garrido, Marina C. Garassino, Fiona McDonald, Françoise Mornex, Andrea R. Filippi, Hans J.M. Smit, Solange Peters, John K. Field, Daniel C. Christoph, Anne Sibille, Rainer Fietkau, Vilde D. Haakensen, Christos Chouaid, Ben Markman, T. Jeroen N. Hiltermann, Alvaro Taus, William Sawyer, Allison Allen, Pratibha Chander, Muriel Licour, Benjamin Solomon. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. Journal of Thoracic Oncology 2023; 18(2) doi: 10.1016/j.jtho.2022.10.003
|
| 197 |
Lærke Rosenlund Nielsen, Simone Stensgaard, Peter Meldgaard, Boe Sandahl Sorensen. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach. Cancer Treatment and Research Communications 2024; 39 doi: 10.1016/j.ctarc.2024.100802
|
| 198 |
Putthapoom Lumjiaktase, Nanthisa Kemawichanurat, Kanthon Santiwiwas, Thatchathum Kuttiyod, Songporn Oranratnachai, Narumol Trachu, Nanamon Monnamo, Khantong Khiewngam, Kantapat Simmalee, Thanyanan Reungwetwattana. Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients. Lung Cancer: Targets and Therapy 2026; doi: 10.2147/LCTT.S578622
|
| 199 |
Shi Tang, Xiaofeng Cong, Dan Zheng, Chen Chen, Zengguang Liu, Jie Gao, Huimin Zhang, Youhao Zhang, Ziling Liu. Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1129989
|
| 200 |
Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Hisashi Tanaka, Megumi Inaba, Terunobu Haruyama, Junya Nakamura, Takayuki Kishikawa, Masanao Nakashima, Keiichi Iwasa, Keiichi Fujiwara, Tadashi Kohyama, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Hiroo Ishida, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Toshihide Yokoyama, Kenichi Gemba, Takeshi Tsuda, Hideyuki Nakagawa, Hirotaka Ono, Tetsuo Shimizu, Morio Nakamura, Sojiro Kusumoto, Ryuji Hayashi, Hiroki Shirasaki, Nobuaki Ochi, Keisuke Aoe, Nobuhiro Kanaji, Kosuke Kashiwabara, Hiroshi Inoue, Nobuhiko Seki. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study). Therapeutic Advances in Medical Oncology 2021; 13 doi: 10.1177/1758835921998588
|
| 201 |
Jinwoo Park, Minji Kim, Seung Lee. No Survival Advantage of Intermediate Radiotherapy Dose Escalation in Stage III NSCLC Receiving Delayed Immunotherapy after Chemoradiation. Asian Journal of Current Research in Clinical Cancer 2026; 6(1) doi: 10.51847/1D1HOZjkgn
|
| 202 |
Yuko Tsuchiya-Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, Katsuya Hirano, Atsushi Horiike, Miyako Satouchi, Shinobu Hosokawa, Ryotaro Morinaga, Kazutoshi Komiya, Koji Inoue, Yuka Fujita, Ryo Toyozawa, Tomoki Kimura, Kosuke Takahashi, Kazuo Nishikawa, Junji Kishimoto, Yoichi Nakanishi, Isamu Okamoto. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer. The Oncologist 2020; 25(6) doi: 10.1634/theoncologist.2019-0746
|
| 203 |
Kang Wang, Fengchang Yang, Changxing Feng, Fuhao Xu, Li Li, Jinghao Duan, Shuanghu Yuan. Dose-Volume Constraints Parameters for Lung Tissue in Thoracic Radiotherapy Following Immune Checkpoint Inhibitor Treatment. Journal of Inflammation Research 2024; doi: 10.2147/JIR.S484489
|
| 204 |
Mitsue Kawamura, Norio Araki, Noriko Kishi, Tatsuya Suwa, Yuki Yamamoto, Osamu Kanai, Kohei Fujita, Misato Okamura, Koichi Nakatani, Tadashi Mio. Retrospective Treatment Outcomes of Concurrent Chemoradiotherapy in Patients with Stage III Non-small Cell Lung Cancer at a Single Institution: The Pre-PACIFIC Era. Haigan 2021; 61(5) doi: 10.2482/haigan.61.383
|